XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at Dec. 31, 2020   $ 6 $ 400,071 $ (746) $ (366,072) $ 33,259
Balance (in shares) at Dec. 31, 2020 573,282 6,246,896        
Loss for the period           (13,363)
Balance at Sep. 30, 2021         (379,434) 41,594
Balance at Dec. 31, 2020   $ 6 400,071 (746) (366,072) 33,259
Balance (in shares) at Dec. 31, 2020 573,282 6,246,896        
Issue of common stock and associated warrants on underwritten offering, net of expenses   $ 2 13,500     13,502
Issue of common stock and associated warrants on underwritten offering, net of expenses (in shares)   2,078,214        
Issue of common stock on At Market, net of expenses   $ 1 3,869     3,870
Issue of common stock on At Market Issuance sales agreement, net of expenses (in shares)   752,425        
Warrant & stock option exercises   $ 1 4,564     $ 4,565
Warrant & stock option exercises (in shares)   915,600       6,600
Stock-based compensation     1,157     $ 1,157
Preferred stock dividends     (201)     (201)
Unrealized foreign exchange on intercompany loans       (2,125)   (2,125)
Translation adjustment       2,123   2,123
Loss for the period         (18,457) (18,457)
Balance at Dec. 31, 2021   $ 10 422,960 (748) (384,529) 37,693
Balance (in shares) at Dec. 31, 2021 573,282 9,993,135        
Accretion on redeemable common stock           (33)
Loss for the period           (8,683)
Balance at Jun. 30, 2022   $ 10 424,010   (393,212) 29,532
Balance at Dec. 31, 2021   $ 10 422,960 (748) (384,529) 37,693
Balance (in shares) at Dec. 31, 2021 573,282 9,993,135        
Accretion on redeemable common stock           (135)
Loss for the period           (13,779)
Balance at Sep. 30, 2022   $ 9 422,542   (398,308) 22,497
Balance at Dec. 31, 2021   $ 10 422,960 (748) (384,529) 37,693
Balance (in shares) at Dec. 31, 2021 573,282 9,993,135        
Issue of common stock on At Market, net of expenses   $ 0 478     478
Issue of common stock on At Market Issuance sales agreement, net of expenses (in shares)   541,542        
Reclassification of redeemable common stock   $ (1) (1,635)     (1,636)
Reclassification of redeemable common stock (in shares)   (1,130,000)        
Accretion on redeemable common stock     (135)     $ (135)
Warrant & stock option exercises (in shares)           0
Stock-based compensation     1,506     $ 1,506
Stock-based compensation (in shares)   17,412        
Preferred stock dividends     (201)     (201)
Unrealized foreign exchange on intercompany loans       (21,166)   (21,166)
Translation adjustment       20,598   20,598
Loss for the period         (21,198) (21,198)
Balance at Dec. 31, 2022   $ 9 422,973 $ (1,316) (405,727) 15,939
Balance (in shares) at Dec. 31, 2022 573,282 9,422,089        
Balance at Mar. 31, 2022         (388,637) 33,840
Reclassification of redeemable common stock   $ (1) (1,071)      
Accretion on redeemable common stock     (33)     (33)
Loss for the period           (4,575)
Balance at Jun. 30, 2022   $ 10 424,010   (393,212) 29,532
Reclassification of redeemable common stock (in shares)   9,422,089        
Accretion on redeemable common stock     (102)     (102)
Loss for the period           (5,096)
Balance at Sep. 30, 2022   $ 9 $ 422,542   $ (398,308) $ 22,497